Pipeline and Commercial Insight: Alzheimer’s Disease

Questions: Discounts, Updates etc.

Price: $22,800.00

Publication Date: 2005-11-07

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Alzheimer’s patients remain poorly treated and are growing in number. Currently, cholinesterase inhibitors and the more recent NMDA-receptor antagonists provide only moderate and temporary symptomatic benefit. By the end of the decade, however, drugs with the ability to slow the rate of disease progression are expected to be launched - most notably, the first beta-amyloid modulators.


Scope

  • Overview of the epidemiology of Alzheimer’s disease across the seven major markets and its diagnosis and management
  • Examination of the Alzheimer’s disease pipeline with clinical and commercial profiles of late-stage candidates, incorporating Datamonitor opinion
  • Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2014
  • Insight and commentary from qualitative interviews with Alzheimer’s disease opinion leaders in the US, Europe and Japan


    • Report Highlights
    The Alzheimer’s disease market is forecast to continue to expand significantly over the next ten years. Aided by growing elderly populations, successive product launches have seen global revenues grow at over 35% CAGR 2001–04.

    A new phase in the treatment of Alzheimer’s disease is expected to begin in 2009 with the launch of drugs that slow the progression of the disease - Alzhemed and Flurizan. Once launched, however, these drugs may not have long before further generations of disease modifying drugs arrive, pushing sales of Alzhemed and Flurizan into decline from 2013.

    Clinical trial design will be key to the success of many new products. Trial duration must be appropriate for the drug’s mechanism of action. Furthermore, selection of individuals from Alzheimer’s disease subgroups or those more likely to get the disease, can lead to better efficacy demonstration and lower required recruitment numbers.


    Reasons to Purchase

  • Understand concerns over efficacy of currently available therapies and the impact of this on AChEI use
  • Identify potential patient segments in Alzheimer’s Disease for key late-stage compounds and rank future products
  • Assess the global sales forecasts of currently marketed products and evaluate the impact of generic galantamine

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegeneration neurodegenerative alzheimers alzheimers pipeline disease alzheimer patent generic market uk insight commercial

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.